Company: APXIF
Filing Date: 2025-03-31
Form Type: F-4/A
Source: 0001213900-25-026339
Chunk: 310

Company: APx Acquisition Corp. I
Filing Date: 2025-03-31
Form: F-4/A
Chunk 310
---
 Answers About the Business Combination and the Special Meeting — What equity stake will our current shareholders and shareholders of the Target hold in OmnigenicsAI immediately after consummation of the Business Combination?”, which includes a table reflecting the post -BusinessCombination ownership of the Company, inclusive of the potential issuance pursuant to the Backstop Agreement. The parties to the Backstop Agreement will benefit from the backstop transactions and the consummation of the Business Combination, which benefits are different from, or in addition to, those available to SPAC Shareholders and warrant holders generally. See the section entitled “ Summary of the Proxy Statement / Prospectus — Interests of Certain Persons in the Business Combination.” Voting and Support Agreement Concurrently with the execution of the Business Combination Agreement, SPAC, the Sponsor, the Company and the Parent have each executed and delivered to the Company and SPAC the Support Agreement, pursuant to which, among other things, the Sponsor agreed to vote any of the Sponsor Current Shares (as defined in the Support Agreement) and any SPAC Ordinary Shares held by the Sponsor in favor of the Business Combination. The Sponsor received no consideration (in cash or other form of value) in exchange for entering into the Voting and Support Agreement. Pursuant to the Support Agreement, Parent agreed to vote any of the Parent Subject Shares (as defined in the Support Agreement) in favor of the Business Combination. Additionally, pursuant to the Support Agreement, the Company shall comply with the requirements of Antitrust Authorities. The Company and Parent, as well as their respective Affiliates, must also comply with Antitrust Laws and requirements set forth by Antitrust Authorities, which include, among other things, (i) obtaining all approvals required under Antitrust Laws, (ii) contestation of adverse rulings that would make any of the Transactions unlawful, (iii) payment of filing fees related to Antitrust Authorities; and (iv) execution and delivery of additional documents necessary to comply with orders of any Antitrust Authority. The foregoing description of the Support Agreement does not purport to be complete and is qualified in its entirety by the terms and conditions of the Support Agreement, a copy of which is filed herewith as Exhibit D to the Business Combination Agreement. 154 IPO Letter Agreement In connection with APx’s IPO, the Initial Sponsor (and, pursuant to amendments subsequent thereto, our Sponsor and Templar Subco) entered into the IPO Letter Agreement, pursuant to which (and for no additional consideration) they have agreed to, among other things (i) waive their redemption